表紙:脱毛症治療(脱毛)市場 - 成長、傾向、および予測(2019年 -  2024年)
市場調査レポート
商品コード
871418

脱毛症治療(脱毛)市場 - 成長、傾向、および予測(2019年 - 2024年)

Alopecia Treatment (Hair Loss) Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 114 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.27円
脱毛症治療(脱毛)市場 - 成長、傾向、および予測(2019年 - 2024年)
出版日: 2020年08月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 114 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは世界の脱毛症治療市場について調査しており、市場について調概況や成長要因・阻害要因、病種・薬剤・投薬ルート・性別・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報をまとめています。

目次

第1章 イントロダクション

  • 研究成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場のダイナミクス

  • 市場概況
  • 市場成長要因
    • 脱毛症の有病率の増加
    • 研究開発への取り組み、および新製品の発売と承認の増加
  • 市場阻害要因
    • 多くの画期的薬剤の特許失効
    • 利用可能な脱毛治療に関連する副作用
  • ポーターファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界の競争

第5章 市場セグメント

  • 病気の種類別
    • アンドロゲン性脱毛症
    • 円形脱毛症
    • 小児脱毛症
    • 牽引性脱毛症
    • 全頭脱毛症
  • 薬の種類別
    • ミノキシジル
    • フィナステリド
    • その他
  • 投薬ルート別
    • 経口
    • 外用
    • 注射
  • 男女別
    • 男性
    • 女性
  • 流通チャネル別
    • 病院
    • 小売薬局
    • オンライン薬局
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東およびアフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Sun Pharmaceuticals Industries Ltd.
    • Aclaris Therapeutics Inc.
    • Cipla Inc.
    • Concert Pharmaceuticals Inc.
    • 第一三共株式会社
    • GlaxoSmithKline PLC.
    • HCell Inc.
    • Histogen Inc.
    • Merck & Co., Inc.

第7章 市場機会および今後の動向

>
目次
Product Code: 64749

Alopecia is a term used to describe excessive hair damage under certain medical conditions or dietary issues. A sedentary lifestyle and unhealthy diets are leading to loss of hair among masses. Furthermore, aging and hormonal imbalance, increasing chronic diseases like arthritis, cancer, hypertension, depression also leads to hair loss, especially among the middle-aged population. According to the American Hair Loss Association, androgenetic alopecia accounts for over 95% of hair loss in men. Over 800 thousand patients are seeking some kind of treatment for hair loss worldwide.

In recent years, many novel drugs have been approved by the regulatory bodies for the treatment of alopecia and many drugs are in pipeline, which are expected to receive approval in the near future. Concert Pharmaceuticals Inc. received fast track designation from the United States Food and Drug Administration, (FDA) for its novel product for the treatment of moderate-to-severe alopecia areata in January 2018. The launches of such novel products in the market is expected to drive the global alopecia treatment market growth in the near future.

Key Market Trends

Female is Expected to Hold Largest Share Over the forecast period

About one-third of women experience hair loss (alopecia) at some time in their lives. Among postmenopausal women, as many as two-thirds suffer hair thinning or bald spots. Hair loss in women often has a greater impact than hair loss does on men, because it's less socially acceptable for them.

Androgenetic alopecia is the most common cause of hair loss in women. Alopecia can severely affect a woman's emotional well-being and quality of life. Although Alopecia is more common in male than female, the female has the largest share in the market owing to the factors such as high awareness levels coupled with increased frequency of Polycystic Ovary Syndrome (PCOS) causing a hormonal imbalance that leads to androgenetic alopecia.

North America Region Holds the Largest Market Share of Alopecia Treatment (Hair Loss) Market

North America dominates the Alopecia Treatment (Hair Loss) market due to the presence of technologically advanced healthcare infrastructure, high disposable income, and availability of novel therapeutics options pertaining to the treatments. According to the United States National Library of Medicine, Alopecia areata affects 1 in every 500 to 1,000 people in the United States. It is one of many recognized forms of alopecia, alopecia areata is the second most common form after androgenetic alopecia. Alopecia areata affects men and women equally, and it can occur in people of any ethnic background. Therefore, the high prevalence and the proportionally high treatment rates pertaining to hair loss in the U.S. are high major drivers for the North American market.

Competitive Landscape

Some of the prominent industry players operating in total Alopecia Treatment (Hair Loss) market include Sun Pharmaceuticals Industries Ltd., Aclaris Therapeutics Inc., Cipla Inc., Concert Pharmaceuticals Inc., Daiichi Sankyo Inc. The development of advanced products for better outcomes and rigorous marketing is one of the competitive strategies adopted by the market players. In 2018, HCell Inc., a biotechnology company received orphan drug designation (ODD) for its product from the FDA. Furthermore, in 2017, Perrigo Company PLC. Launched over-the-counter Women's Rogaine, which helps to regrow hair on top of the scalp.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Alopecia
    • 4.2.2 Increasing R&D Initiatives and New Product Launches and Approvals
  • 4.3 Market Restraints
    • 4.3.1 Patent Expiry of Many Blockbuster Drugs
    • 4.3.2 Side Effects Associated with the Available Hair Loss Treatment Therapies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Disease Type
    • 5.1.1 Androgenic Alopecia
    • 5.1.2 Alopecia Areata
    • 5.1.3 Ciatricial Alopecia
    • 5.1.4 Traction Alopecia
    • 5.1.5 Alopecia Totalis
  • 5.2 By Gender
    • 5.2.1 Male
    • 5.2.2 Female
  • 5.3 By Route of Administration
    • 5.3.1 Oral
    • 5.3.2 Topical
    • 5.3.3 Injectable
  • 5.4 By Distribution Channel
    • 5.4.1 Hospitals
    • 5.4.2 Retail Pharmacies
    • 5.4.3 Online Pharmacies
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Aclaris Therapeutics Inc.
    • 6.1.2 Cipla Inc.
    • 6.1.3 Concert Pharmaceuticals Inc.
    • 6.1.4 Daiichi Sankyo Inc.
    • 6.1.5 GlaxoSmithKline PLC
    • 6.1.6 HCell Inc.
    • 6.1.7 Johnson & Johnson
    • 6.1.8 Merck & Co. Inc.
    • 6.1.9 Sun Pharmaceuticals Industries Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS